Development Stage
Product Candidate
Target Indication
Discovery
Pre-clinical
Phase1
Phase2
Phase3
AFX-001
SOT
GvHD
SOT
- Stage : Discovery
- Cell type : Engineered MSC
- MoA : Suppression of T-cell mediated B-cell activation
- Target : undisclosed
- Dose Route : Intravenous Injection
- Pre-clinical stage will begin in 2022
GvHD
- Stage : Discovery
- Cell type : Engineered MSC
- MoA : Suppression of T-cell mediated B-cell activation
- Target : undisclosed
- Dose Route : Intravenous Injection
- Pre-clinical stage will begin in 2022
AFX-002
MS
MS
- Stage : Discovery
- Cell type : Engineered MSC
- MoA : Inhibition of T-cell proliferation & cytokine production
- Target : undisclosed
- Dose Route : Intravenous Injection
- Pre-clinical stage will begin in end of 2022